Articles tagged with Cancer
A study by Wake Forest University School of Medicine reveals that a stress response in immune cells contributes to chemotherapy-induced nerve damage. By blocking this pathway, researchers aim to develop new treatments to protect cancer patients from debilitating side effects.
Researchers at Cincinnati Children's discovered a specific gene mutation in 'cold' tumors that block immune checkpoint inhibitors. Rapamycin was found to make these tumors responsive again by inhibiting mTORC1 signaling.
Researchers discovered a unique protein in bowhead whales that repairs damaged DNA, potentially contributing to their remarkable longevity. The protein, CIRBP, is present at 100-fold higher levels in bowhead whales compared to other mammals.
A new study suggests that collecting and testing cancer cells in patients' blood could help doctors choose the right breast cancer treatment. The 'labyrinth chip' technology separates cancer cells from other blood cells, allowing researchers to identify biomarkers that distinguish aggressive treatments from less invasive ones.
Dr. Jonathan D. Licht, a renowned expert in blood cancer and epigenetics, will succeed Peter A. Jones as the next president and chief scientific officer of Van Andel Institute. Licht's extensive research experience and leadership skills will further strengthen the Institute's efforts to improve health and lives.
Artificial intelligence is transforming cancer prevention, detection, and treatment by connecting technology with people. AI-driven public-health analytics, patient-doctor relationships, and diverse clinical research are crucial for delivering immediate benefit to patients, clinicians, and policymakers.
A Johns Hopkins-led study has found that two analgesic drugs, bupivacaine and rimegepant, can slow the growth of osteosarcoma tumors by inhibiting nerve signaling. The researchers tested these medications in mice with osteosarcoma-like tumors and observed a significant reduction in tumor growth and spread.
Cancer Communications, a new journal published through the AAAS Science Partner Journal program, aims to bridge global oncology insights and clinical impact. The journal welcomes submissions on various cancer research topics, including clinical trials, epidemiology, and molecular biology.
The Mays Cancer Center stands among the nation's leading institutions recognized for excellence in cancer care and research. It is one of only four NCI-designated Cancer Centers in Texas, offering specialized programs and delivering comprehensive, multidisciplinary care supported by clinical research.
Researchers developed a computational platform to design synthetic protein receptors that can detect tumor signals and boost T cell activity. The new receptors, called T-SenSERs, showed improved tumor control and longer survival in mouse models of lung cancer and multiple myeloma.
Researchers have developed vitamin-engineered nanoplatforms that can overcome tumor heterogeneity and therapeutic resistance. These platforms integrate immunomodulation, precision drug delivery, and diagnostic capabilities, enabling targeted therapy and early detection of cancer.
The WNT signaling pathway is a double-edged sword in human health, promoting tumor growth and resistance to therapy while offering therapeutic targets. Recent advances in understanding this pathway aim to harness it for cancer treatment, with focus on improving drug specificity and combination therapies.
Recent review article highlights how single-cell multi-omics technologies are deciphering the intricate heterogeneity of biliary tract cancers. Researchers can now analyze genetic, transcriptomic, and epigenetic facets of individual cells within a tumor.
Scientists have identified a new biomarker, F2R, which could improve ovarian cancer diagnosis and treatment. Elevated F2R levels are associated with shorter life spans, making it a valuable prognostic indicator.
A recent randomized controlled pilot study suggests that Baduanjin, a traditional Chinese mind-body exercise, may help alleviate menopausal symptoms and fatigue in breast cancer patients undergoing aromatase inhibitor therapy. The study found significant improvements in joint pain and cognitive/mood dimensions of fatigue.
The intra-tumoral microbiome influences cancer initiation, progression, and immune regulation through various mechanisms. Targeting the tumor microbiota holds promise for precision medicine and cancer therapy.
Researchers have uncovered a new mechanism by which the body's immune system responds to viral infections, potentially leading to a new approach for fighting cancer. The study reveals that infected cells produce their own unique RNA signal, Z-RNA, which sets off a chain reaction leading to cell death before viruses can hijack them.
A blood test detecting tiny fragments of cancer DNA can help tailor chemotherapy to individual patients with stage 3 colon cancer. The DYNAMIC-III study found that patients with low-risk levels had an 87% cancer-free rate three years after surgery, while those with high-risk levels had a much higher risk of recurrence.
A study by researchers at Umeå University found that high levels of HIF2α protein can reduce tumour growth and promote maturation of neuroblastoma cells. The findings challenge previous views on the role of HIF2α in cancer development.
Researchers at Hebrew University of Jerusalem have created a new type of drug molecule that can precisely destroy TERRA, an RNA molecule helping certain cancer cells survive. The discovery paves the way for a new generation of RNA-based cancer treatments targeting genetic roots rather than symptoms.
Scientists have characterized lipid nanoparticles' internal shape and structure, which correlates with how well they deliver therapeutic cargo. The research provides a blueprint for engineering more effective RNA therapies by matching LNP designs to specific therapies and tissues.
A team of researchers developed a battery-free wearable patch that measures bioimpedance to detect skin lesions, distinguishing between healthy and abnormal skin. The patch's effectiveness was tested on 10 volunteers, showing significant differences between healthy and suspicious moles.
Patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer. The vaccine was associated with a near doubling of median survival, from 20.6 months to 37.3 months in lung cancer patients.
A major study of breast, cervical, and ovarian cancers found significant inequalities in global care, with many low- and middle-income countries (LMICs) diagnosing cancer at a later stage. Surgery was offered consistently, but treatment consistency varied, with LMICs often choosing mastectomy over breast-conserving surgery.
A new technique allows researchers to track the distribution of chemotherapy drugs within cancer cells, enabling more accurate determination of treatment effectiveness. This breakthrough could pave the way for personalized cancer therapies.
A new study found that adding chemotherapy to radiation therapy causes a greater decline in quality of life for women with early-stage cervical cancer. The trial measured patient-reported outcomes, including symptoms and side effects, highlighting the need for supportive care during treatment.
A new blood-based liquid biopsy model, LiBIO score, predicts immunotherapy response with high accuracy. The model identifies an early post-treatment time point as optimal for assessing treatment response and can help identify patients who are more likely to benefit from immunotherapy.
Researchers use mathematical modeling to estimate how vaccination, screening, and treatment collectively drive elimination. Studies show that with sustained investment and policy coordination, cervical cancer could be eliminated within decades in high-income countries and within the next century globally. The models also reveal cost-ef...
UofL Health – Brown Cancer Center oncologists and researchers will continue developing novel therapies using patients' own immune system to defeat cancer. The center's faculty and research facilities support clinical trials that bring new treatments to patients.
The Mount Sinai Tisch Cancer Center has been named a Comprehensive Cancer Center by the National Cancer Institute, recognizing its breadth and depth of cancer research, clinical excellence, and commitment to health equity. The center will receive over $3 million annually in funding to support its research and innovation.
A rare case of pancreatic Hodgkin lymphoma was reported, emphasizing the need for tissue diagnosis before definitive treatment. The patient's symptoms and imaging findings initially raised concern for pancreatic adenocarcinoma, but a biopsy revealed nodular sclerosis subtype of Hodgkin lymphoma.
Researchers at Tokyo University of Science identified genes that predict CD8+ T cell expansion in cancer immunotherapy. A 'signature gene set' or 'expansion signature' was found to identify primed T cells for growth, predicting treatment response and offering a potential guide for new therapies.
Researchers create enhanced T cells with improved survival in cancer models by simultaneously modifying multiple genes using CRISPRoff and CRISPRon. The approach overcomes toxicity issues associated with traditional gene editing methods, enabling high cell survival rates and potential for treating various diseases.
Researchers have discovered a novel compound that degrades key proteins found in prostate cancer cells, blocking oncogenic androgen receptor signaling. The study found that levels of H2BNTac, p300 and CBP are elevated in prostate cancer compared to normal tissue.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
The study found that using circulating tumor DNA to guide treatment resulted in fewer recurrences, hospitalizations, and treatment side effects among patients who tested negative for ctDNA. Patients with positive results did not see improved outcomes from escalated therapy.
Researchers discover that gray hair may be a result of a natural defense mechanism against cancer, where damaged stem cells undergo senescence-coupled differentiation, leading to graying. In contrast, bypassed stem cells can expand clonally and lead to tumor development.
A recent study published in CANCER found that the number and complexity of cancer clinical trials have varied greatly across low- and middle-income countries (LMICs) since 2001. While economic growth has been a contributing factor, it is not the sole determinant of cancer clinical trial growth among LMICs.
A surveillance study found that cancer incidence rates for 13 types of cancer rose in both younger and older adults worldwide, with increases related to obesity. This analysis suggests that research priorities should consider cancer types seen rising in both age groups.
Researchers at University of California San Diego have developed an AI-based method to target cancer stem cells, which can spread and resist therapy. The approach leverages machine learning to identify treatment targets and restore function to genes, leading to the self-destruction of cancer cells.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
A periodized exercise program can improve physical function, reduce treatment-related fatigue, and enhance overall quality of life for cancer patients. Research shows that tailored exercise plans can also positively influence systemic inflammation, metabolism, and immune function, which could impact cancer progression and recurrence.
A new digital health program has been found to significantly increase lung cancer screening rates among people at high risk. The study, which tested a direct-to-patient program, showed that 24.5% of participants completed a screening CT scan within 16 weeks, compared to 17% in the usual care group.
Researchers found that combining zanzalintinib, a targeted therapy drug, with atezolizumab, an immune checkpoint inhibitor, improved survival rates by 20% compared to standard treatment regorafenib. The new combination also delayed cancer progression and showed promising results in patients with metastatic colorectal cancer.
A blood test that detects circulating tumor DNA (ctDNA) can help guide post-surgical immunotherapy for patients with muscle-invasive bladder cancer. The test identified a benefit in patients with positive ctDNA, who experienced reduced disease recurrence and death risk compared to those without.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A team of researchers identified a unique protein signature that can predict which patients are likely to resist standard therapies, paving the way for personalized treatments. By blocking a specific transporter system, they made tumors more sensitive to treatment, suggesting a promising new avenue for treating colorectal cancer.
A recent study found that patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine. The observation marks a significant step toward a long-awaited universal cancer vaccine to boost tumor-fighting eff...
A team of scientists has created a detailed model of how cells regulate traffic through the nuclear pore complex, revealing that flexible protein chains create an entropic barrier that admits only properly escorted cargo. This breakthrough sheds light on diseases like cancer, Alzheimer's, and ALS, where this transport system fails.
A clinical trial showed a new drug combination reduced deaths in patients with recurrent prostate cancer after surgery or radiation therapy. The combination of hormone therapy and enzalutamide cut the risk of death by 40%, offering a meaningful treatment option for high-risk patients.
Researchers found a protein that lets cancer cells reshape their mitochondria to protect themselves from venetoclax, a standard treatment for acute myeloid leukemia. Blocking this protein with experimental compounds restored the drug's effectiveness and prolonged survival in mice.
The study reveals geographic clusters of high and low screening for breast, cervical, and colorectal cancers in the US Northeast and Southwest. Future studies could examine county-level healthcare access to optimize cancer screening practices.
The European Society of Endocrinology has released the EndoCompass Research Roadmap, a major new initiative to align research efforts and improve funding strategies for hormone-related health challenges. The roadmap identifies specific research needs across eight endocrine specialties and five cross-cutting areas.
Researchers developed TAMENDOX to supplement (Z)-endoxifen in patients with CYP2D6 enzyme deficiency, improving drug concentration and effectiveness. The new therapy was well-tolerated, showing promise as an alternative to aromatase inhibitors for premenopausal women.
Cancer cells hijack embryonic gene editors to drive rapid growth and adaptation. Researchers discovered that cancer cells activate early developmental splicing factors to create embryo-like potential. This finding may lead to new treatments by detecting splicing factor changes or targeting specific editing tools.
Researchers found that group-based interventions, mindfulness-based techniques, and expressive therapies can reduce emotional distress and build resilience in people with cancer. CHMs like peer support and psychoeducation help patients reclaim their sense of self.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
Researchers identified 5.05% of individuals carrying pathogenic variants in key cancer susceptibility genes, highlighting a significant association between these genetic variations and increased cancer risk. The study suggests that more extensive genetic screening for these genes may be warranted to identify high-risk individuals.
Researchers at UZH have identified a new function of checkpoint inhibitors in promoting tissue healing, which could help treat fibrosis and chronic wounds. The study found that TIGIT upregulates a growth factor critical for repairing tissue after viral infections.